Article Text

Download PDFPDF

4CPS-125 Preexposure prophylaxis in men at high risk for HIV-1 infection
  1. EM Barreiro Fernandez1,
  2. CM Dominguez Santana2,
  3. E Rios Sanchez2,
  4. MA Blanco Castaño3,
  5. FJ Salmeron Navas4
  1. 1Hospital Universitario Puerto Real, Servicio de Farmacia, Cadiz, Spain
  2. 2Hospital Universitario Puerto Real, Farmacia Hospitalaria, Cadiz, Spain
  3. 3Hospital Universitario Farmacia, Farmacia Hospitalaria, Cadiz, Spain
  4. 4Hospital Pozoblanco, Farmacia Hospitalaria, Cordoba, Spain


Background and Importance The Preexposure Prophylaxis (PrEP) for HIV infection with the drugs tenofovir and emtricitabine (FTC/TDF) is recommended by World Health Organization as part of HIV prevention to people at substantial risk HIV infection. Many countries have included it in their healthy police. However, there is a lack of information on its implementation in real practice.

Aim and Objectives To evaluate adherence, the effectiveness and safety to treatment for PrEP.

Material and Methods A retrospective and descriptive study of all adult patients who used FTC/TDF for PrEP from September 2020 to September 2022. Clinical data were obtained from digital clinical history and the prescription software Dominion®: sex, age, duration of treatment, high-risk for HIV and adherence to treatment.

The adherence to treatment was measured using the dispensing registry. Effectiveness was determined by relative reduction of HIV incidence; HIV testing was performed every three months during this study. In terms of safety, adverse events (AE) were recorded.

Results Forty patients, 100% men, were included, with an average aged of 35 (20-57) years. All patients were received (FTC/TDF), once daily. The average duration of treatment was 6 months (1-30), 8 patients received only two months. All patients were at high risk for HIV, defined as: sexual risk behaviour (ten or more sexual partners and any bacterial sexually transmitted infections (STIs) last year). 25% patients had discontinued therapy due to lack of adherence.

None of these patients were diagnosed HIV during study. 100% relative reduction of HIV incidence.

No treatment-associated adverse effects were observed, although 75% of patients had PrPE-associated bacterial STIs.

Conclusion and Relevance

  • A quarter of patients were non-adherent to treatment, a possible alternative would be on-demand regimen in these cases.

  • In terms of efficacy, a greater therapeutic result was observed, becoming a good tool prevention.

  • PrEP used was associated high increased bacterial STIs, probably due to not using a condom.

Conflict of Interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.